Top

Published in:

01-02-2023 | Etanercept | Clinical study

Biological and target synthetic DMARDs have differing infection risks

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Biological disease-modifying antirheumatic drugs (bDMARDs) and target synthetic DMARDs (tsDMARDs) have generally similar safety profiles but some differences in infection risks, according to findings of a nationwide Swedish study published in Annals of Rheumatic Diseases . …

Frisell T, et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Annals of the Rheumatic Diseases : 14 Feb 2023. Available from: URL: http://doi.org/10.1136/ard-2022-223762

Title: Biological and target synthetic DMARDs have differing infection risks
Publication date: 01-02-2023
Publisher: Springer International Publishing
Keywords: Etanercept
Disease Modifying Anti-Rheumatic Drug
Certolizumab
Golimumab
Abatacept
Tocilizumab
Rituximab
Rituximab
Sarilumab
Anakinra
Shingles
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-34088-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biological and target synthetic DMARDs have differing infection risks

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Convalescent anti sars cov 2 plasma

Crizotinib

Ciclosporin/immune-globulin/mycophenolate-mofetil

Bbv-152

Levofloxacin

Imatinib